Will the high-priced Hemgenix be reimbursed in Korea?
By Whang, byung-woo | translator Alice Kang
24.09.23 05:43:53
가나다라
0
The first and only one-time gene therapy for people with hemophilia B
CSL Behring is expected to apply for reimbursement next year… its high price of KRW 4.7 billion (based on U.S. price) is expected to act as a barrier
Company would need to appeal to the drug’s strengths such as its effect compared to lifelong treatment
The reimbursement listing process for Hemgenix (etranacogene dezaparvovec-drlb), a 'one-shot' treatment for hemophilia B that shows its effect as a single dose that received domestic approval recently, has been gaining attention in Korea.
▲Pic of Hemgenix
According to industry sources on the 21st, the Ministry of Food and Drug Safety (MFDS) recently approved CSL Behring Korea's hemophilia B gene therapy Hemgenix for the treatment of hemophilia B in adults. Hemgenix is used to treat moderate-to-severe hemophilia B (congenital blood clotting factor IX deficiency) in adults without a history of Factor IX inhibitors.
Hemophilia is divided into two types, hemophilia A and hemophilia B, based
Whang, byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)